Navigation Links
ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
Date:9/11/2009

LEUVEN, Belgium, September 11 /PRNewswire-FirstCall/ --

- ThromboGenics' Significant Achievements Over the Last Year are Recognised in Nominations

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announced today that it has been shortlisted for both the "Biotech Company of the Year" and "Licensing Deal of the Year" awards at the Scrip Awards 2009. These nominations recognise the transformational year that ThromboGenics has had, and the progress it has made toward becoming a profitable, integrated Company focused on cutting edge ophthalmic medicines.

The Biotech Company of the Year award recognises the progress and achievement a biotech company has made within the last twelve months. During the period, ThromboGenics has started the pivotal transatlantic Phase III programme with microplasmin for back of the eye disease, signed a EUR500 million partnership deal with Roche for its novel anti-cancer antibody TB-403, and moved its novel anti-coagulant TB-402 into Phase II trials. TB-402 is another potential partnership opportunity. There are four other companies nominated in this category.

The Licensing Deal of the Year award acknowledges the achievement of a Company in signing a licensing deal that has both monetary and strategic benefits to all parties. ThromboGenics signed a major partnership deal with Roche for TB-403 under which the Company and co-development partner BioInvent received an upfront payment of EUR50 million, an additional EUR450 million in potential milestones, and double digit royalties on future product sales. There are four other licensing deals nominated in this category.

The Scrip Awards is one of the biotechnology and pharmaceutical industry's most prestigious and highly contested awards event. The event is in its fif
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Steep Hill, the ... US and internationally, intends to open a full service ... New Mexico , bringing advanced scientific tools and ... Steep Hill is currently the only laboratory ... conduct potency and contaminant testing in order to meet ...
(Date:2/26/2015)... , Feb. 26, 2015 S&P Capital ... Factual Stock Report coverage on MabVax Therapeutics Holdings Inc ... is a clinical stage biotechnology company focused on the ... medical needs in the treatment of cancer. MabVax has ... on the protective immune responses generated by patients who ...
(Date:2/26/2015)... MOUNTAIN VIEW, Calif. , Feb. 26, 2015 /PRNewswire/ ... appointment of Kate Black as Privacy Officer ... international, federal, and state privacy laws as well as ... and regulatory team, she will be responsible for reviewing, ... for customers in the U.S. and abroad. She joined ...
(Date:2/26/2015)... LEXINGTON, Mass., Feb. 26, 2015   Synageva ... a biopharmaceutical company developing therapeutic products for rare ... and provided 2015 goals, other key objectives, and ... conference call today at 4:30 p.m. EST to ... business update.  To participate in today,s call by ...
Breaking Biology Technology:Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 523andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... Intercell,s IXIARO, the first licensed vaccine against Japanese ... -- This final decision follows the positive opinion ... in December 2008VIENNA, April 2 Intercell AG ... to prevent Japanese Encephalitis, IXIARO(R), has been approved ...
... for detection of methicillin-resistant Staphylococcus aureus for better patient ... its new LightCycler(R) test for the detection of methicillin-resistant ... the CE Mark, allowing it to be sold for ... Advanced Test is a qualitative in vitro ...
... - Conference Call Scheduled for Today at 5:00 p.m. ... Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) ... fiscal year ended December 31, 2008.Total revenue for the ... a net loss of $37.2 million. As of December ...
Cached Biology Technology:Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis 2Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis 3Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis 4Roche to Introduce New LightCycler(R) MRSA Advanced Test in the EU 2Roche to Introduce New LightCycler(R) MRSA Advanced Test in the EU 3Roche to Introduce New LightCycler(R) MRSA Advanced Test in the EU 4Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 2Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 3Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 4Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 5Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 6Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 7Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 8Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 9Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 10Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 11
(Date:2/5/2015)... , Feb. 3, 2015 Despite a ... from industries such as consumer electronics, automotive, storage ... surface mount technology (SMT) screen printers. Innovations in ... control will push the adoption curve up. Meanwhile, ... steady as glue dispensers are indispensable in the ...
(Date:1/22/2015)... Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), ... crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz ... production capacity to meet customer demand. ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by ...
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication ... success of the Wocket™ smart wallet at CES 2015 in ... as one of the "11 Hot Products at CES" in a review ... So Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... PORTLAND, Ore. -- Pediatric neuroscientists at Oregon Health & ... use high magnetic field strength MRI to reveal tiny ... using standard MRI. Early, accurate identification of ... delays in therapy and enable physicians to inform families ...
... Steven B. Abramson, MD, senior vice president and vice ... Departments of Medicine and Pathology at NYU Langone Medical ... American College of Rheumatology (ACR) & Association of Rheumatology ... Chicago. The Distinguished Basic Investigator Award is a ...
... the RIKEN Brain Science Institute (BSI) have discovered a ... proteins from the cell. Their findings indicate that the ... the phosphorylation of a protein called p62, opening the ... as Huntington,s disease and Alzheimer,s disease. One of ...
Cached Biology News:First use of high-field MRI in developing brain reveals previously undetectable injuries 2Steven B. Abramson, MD, receives distinguished Basic Investigator Award at ACR 2011 2